Overall, these studies may suggest MYSM1 as a drug-target for cMYC driven hematologic malignancies; and the Mysm1DN mouse strain described in our current work will allow to test whether the loss of MYSM1 DUB catalytic function can offer similar therapeutic benefits. Here, MYSM1 is linked to hematologic disorder.